Advance your B-Cell Acute Lymphoblastic Leukemia Drug Development with Confidence
Identify your pipeline's most promising therapeutic candidates in our Systemic B-ALL In Vivo Screen, featuring 8 fully characterized B-Cell Acute Lymphoblastic Leukemia PDX models derived from primary patient samples. These models preserve key clinical characteristics of the cancer and are engrafted into severely immunodeficient mice to maintain patient-specific traits. This screen includes model CTG-2408, derived from a patient unresponsive to CD19-targeted CAR-T therapy post-collection, offering valuable insights for targeted therapeutic development.
8 Clinically Relevant Models
Living & diverse bank of 8 clinically relevant models that correlate with clinical outcomes
Pretreated PDX Models
Established from tumor biopsies from patients pretreated with latest generation therapies
Multi-omic Characterization
Clinical annotations coupled with molecular datasets and in vivo responses
Champions' leading systemic B-ALL In Vivo Screen showcases primary PDX models, each reflecting key clinical characteristics, mutations, and pretreatment history.
-
Includes models pretreated with advanced cancer therapies post-collection such as CAR-T and those resistant to targeted treatments and the latest immunotherapies.
-
Offers comprehensive terminal peripheral blood and bone marrow analysis utilizing Champions' high-complexity flow cytometry endpoint, including markers such as hCD10, hCD45, mCD45, hCD3, hCD19, hCD22, hCD20, and Viability Dye.
-
Complete model characterization (clinical data, NGS analysis, proteomics, phospho-proteomics, and more).
-
Opt for additional endpoint analysis: Plasma-based Luminex for quantifying immune modulation responses (available upon request).
-
No minimum to enroll & 50% off a Standard of Care Agent arm (selected by Champions)
Terminal Flow Cytometry Analysis was conducted on two models, CTG-2408 and CTG-2447, post-application of CHOP, R-CHOP, and Venetoclax therapies.